Business · 11/03/1994Updated: 10/15/2026 · 1 min read
Determination of Regulatory Review Period for Purposes of Patent Extension; PRO OSTEON TM Implant 500 Coralline Hydroxyapatite Bone Void Filler
Summary
The US Food and Drug Administration (FDA) has determined the regulatory review period for PRO OSTEON TM Implant 500 Coralline Hydroxyapatite Bone Void Filler and is publishing this notice as required by law.
Original source language: Federal Register — Health and Human ServicesOpen original release →